Valion Bio
VBIO
11 hedge funds and large institutions have $96.3K invested in Valion Bio in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
55% less capital invested
Capital invested by funds: $216K → $96.3K (-$119K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$12.2K |
| 2 |
Millennium Management
New York
|
+$3.86K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.64K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.93K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$429 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$81.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$13.1K |
| 3 |
E
Ergoteles
New York
|
-$4.28K |
| 4 |
Goldman Sachs
New York
|
-$1.57K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$857 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSWM
1
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
| $63.8K | – | – | – |
|
|
TSS
2
Two Sigma Securities
New York
| $10.3K | +$12.2K | +57 | New |
|
|
BFM
3
Boothbay Fund Management
New York
| $3.62K | +$429 | +2 | +11% |
|
|
4
Millennium Management
New York
| $3.2K | +$3.86K | +18 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $3.14K | -$13.1K | -61 | -78% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $3.09K | +$1.93K | +9 | +113% |
|
|
CSS
7
Cubist Systematic Strategies
Stamford,
Connecticut
| $3.03K | +$3.64K | +17 | New |
|
|
OGC
8
One68 Global Capital
New York
| $2.02K | – | – | – |
|
|
HF
9
HRT Financial
New York
| $2K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1.17K | – | – | – |
|
|
11
Osaic Holdings
Scottsdale,
Arizona
| $941 | -$857 | -4 | -44% |
|
12
Wells Fargo
San Francisco,
California
| $20 | – | – | – |
|
|
WAM
13
Warberg Asset Management
Winnetka,
Illinois
| – | -$81.6K | -319 | Closed |
|
|
E
14
Ergoteles
New York
| – | -$4.28K | -17 | Closed |
|
|
15
Goldman Sachs
New York
| – | -$1.57K | -6 | Closed |
|
VBIO Hedge Fund Activity: Q2 2023 in Review
11 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q2 2023, worth a combined $96.3K — down 55% from $216K a quarter earlier.
Fund positioning in VBIO was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $12.2K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $81.6K sold.
- 11 institutional investors held Valion Bio (VBIO) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $96.3K of Valion Bio stock for Q2 2023, down 55% quarter-over-quarter.
- 3 funds opened new Valion Bio positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Valion Bio buyer in Q2 2023 was Two Sigma Securities, an estimated $12.2K added.
- The largest Valion Bio seller in Q2 2023 was Warberg Asset Management, an estimated $81.6K sold.
Based on aggregated 13F filings for Q2 2023.